Page 117 - 中国全科医学2022-14

·1778· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

characteristics and risk factors of drug-induced lung injury by and bioactivation of toxicants in the lung. The in vitro cellular
ALK tyrosine kinase inhibitors：a single center retrospective approach［J］. Exp Toxicol Pathol，2005，57（Suppl 1）：189-
analysis［J］. Thorac Cancer，2020，11（6）：1495-1502. 204. DOI：10.1016/j.etp.2005.05.008.
DOI：10.1111/1759-7714.13416. ［44］ISRAEL-BIET D，LABRUNE S，HUCHON G J. Drug-induced
［31］GURULE N J，HEASLEY L E. Linking tyrosine kinase inhibitor- lung disease：1990 review［J］. Eur Respir J，1991，4（4）：
mediated inflammation with normal epithelial cell homeostasis and 465-478.
tumor therapeutic responses［J］. Cancer Drug Resist，2018， ［45］LI L，MOK H，JHAVERI P，et al. Anticancer therapy
1：118-125. DOI：10.20517/cdr.2018.12. and lung injury：molecular mechanisms［J］. Expert Rev
［32］SOUBRIER M，JEANNIN G，KEMENY J L，et al. Organizing Anticancer Ther，2018，18（10）：1041-1057. DOI：
pneumonia after rituximab therapy：two cases［J］. Joint 10.1080/14737140.2018.1500180.
Bone Spine，2008，75（3）：362-365. DOI：10.1016/j. ［46］Cancer Therapy Evaluation Program DoCTaDNCINIoH. Common
jbspin.2007.10.009. Terminology Criteria for Adverse Events，2017［EB/OL］.
［33］BURTON C，KACZMARSKI R，JAN-MOHAMED R. Interstitial ［2021-06-16］. http：//ctep.cancer.gov.
pneumonitis related to rituximab therapy［J］. N Engl J Med， ［47］HAYASHI M，TAKAYASU H，TADA，et al. Azacitidine-induced
2003，348（26）：2690-2691；discussion2690-1. DOI： pneumonitis in a patient with myelodysplastic syndrome：first case
10.1056/NEJM200306263482619. report in Japan［J］. Intern Med，2012，51（17）：2411-2415.
［34］LARSEN B T，CHAE J M，DIXIT A S，et al. Clinical and DOI：10.2169/internalmedicine.51.8167.
histopathologic features of immune checkpoint inhibitor-related ［48］PEREZ-ALVAREZ R，PEREZ-DE-LIS M，DIAZ-LAGARES
pneumonitis［J］. Am J Surg Pathol，2019，43（10）：1331- C，et al. Interstitial lung disease induced or exacerbated by
TNF-targeted therapies：analysis of 122 cases［J］. Semin
1340. DOI：10.1097/PAS.0000000000001298.
［35］BALA-HAMPTON J E，BAZZELL A F，DAINS J E. Clinical Arthritis Rheum，2011，41（2）：256-264. DOI：10.1016/j.
semarthrit.2010.11.002.
management of pneumonitis in patients receiving anti-PD-1/PD-L1
［49］KUINT R，LOTEM M，NEUMAN T，et al. Organizing pneumonia
therapy［J］. J Adv Pract Oncol，2018，9（4）：422-428.
following treatment with pembrolizumab for metastatic malignant
［36］KALISZ K R，RAMAIYA N H，LAUKAMP K R，et al. Immune
melanoma-a case report［J］. Respir Med Case Rep，2017，20：
checkpoint inhibitor therapy-related pneumonitis：patterns and
95-97. DOI：10.1016/j.rmcr.2017.01.003.
management［J］. Radiographics，2019，39（7）：1923-1937.
［50］GKIOZOS I，KOPITOPOULOU A，KALKANIS A，et al.
DOI：10.1148/rg.2019190036.
Sarcoidosis-like reactions induced by checkpoint inhibitors［J］.
［37］SHIMADA S，ANDO T，YOKOTA T，et al. Severe interstitial
J Thorac Oncol，2018，13（8）：1076-1082. DOI：10.1016/j.
lung disease after one cycle of nivolumab treatment in a patient with
jtho.2018.04.031.
advanced gastric cancer［J］. Nihon Shokakibyo Gakkai Zasshi，
［51］COULIER B，COLIN G C，BENIUGA G. Amiodarone-induced
2019，116（2）：153-160. DOI：10.11405/nisshoshi.116.153.
cryptogenic organizing pneumonia （COP）［J］. Diagn Interv
［38］KOYAMA N，IWASE O，NAKASHIMA E，et al. High incidence
Imaging，2020，101（9）：623-625. DOI：10.1016/j.
and early onset of nivolumab-induced pneumonitis：four case
diii.2020.01.004.
reports and literature review［J］. BMC Pulm Med，2018，18（1）：
［52］HEGADE V S，SOOD R，SARALAYA D，et al. Pulmonary
23. DOI：10.1186/s12890-018-0592-x.
complications of treatment with pegylated interferon for hepatitis C
［39］KIMURA A，SAKAI D，KUDO T，et al. Nivolumab-induced
infection-two case reports［J］. Ann Hepatol，2013，12（4）：
interstitial lung disease in a patient with gastric cancer［J］.
629-633.
Oxf Med Case Reports，2019，2019（2）：omz007. DOI：
［53］CASANOVA M J，CHAPARRO M，VALENZUELA C，et al.
10.1093/omcr/omz007.
Adalimumab-induced interstitial pneumonia in a patient with
［40］BABA T，SAKAI F，KATO T，et al. Radiologic features of
Crohn's disease［J］. World J Gastroenterol，2015，21（7）：
pneumonitis associated with nivolumab in non-small-cell lung
2260-2262. DOI：10.3748/wjg.v21.i7.2260.
cancer and malignant melanoma［J］. Future Oncol，2019，15（16）：
［54］PICIUCCHI S，DUBINI A，TOMASSETTI S，et al. A case of
1911-1920. DOI：10.2217/fon-2019-0102.
amiodarone-induced acute fibrinous and organizing pneumonia
［41］NISHINO M，RAMAIYA N H，AWAD M M，et al. PD-1
mimicking mesothelioma［J］. Am J Respir Crit Care Med，2015，
inhibitor-related pneumonitis in advanced cancer patients：
191（1）：104-106. DOI：10.1164/rccm.201405-0844IM.
radiographic patterns and clinical course［J］. Clin Cancer Res， ［55］李珊，孙宇新，黄慧，等 . 免疫检查点抑制剂相关性间质性肺
2016，22（24）：6051-6060. DOI：10.1158/1078-0432.ccr-
疾病的诊疗进展［J］. 中华结核和呼吸杂志，2018，12（41）：
16-1320. 971-974. DOI：10.3760/cma.j.issn.1001-0939.2018.12.014.
［42］YAMASAKI M，TANIWAKI M，KAWAMOTO K，et al. LI S，SUN Y X，HUANG H，et al. Immune checkpoint
Durvalumab-induced organizing pneumonia with a diffuse inhibitors-associated interstitial lung disease［J］. Chin J Tuberc
micronodular pattern in a patient with lung cancer［J］. Am Respir Dis，2018，12（41）：971-974. DOI：10.3760/cma.
J Respir Crit Care Med，2020，201（8）：e52-53. DOI： j.issn.1001-0939.2018.12.014.
10.1164/rccm.201907-1310IM. （收稿日期：2021-12-19；修回日期：2022-01-15）
［43］CASTELL J V，DONATO M T，GÓMEZ-LECHÓN M J. Metabolism （本文编辑：崔莎）